SageTech Medical's Climate Report

Download as pdf

Introduction *

Commitment and Targets *

Own Emissions *

Value Chain Emissions *

(optional)

Climate Solutions *

(optional)

Management, Strategy and Climate Risk *

(optional)

Results, Challenges and Outlook *

Version 1.1.0

Introduction *

1.1 Reporting year

*

2024

1.1.1 Reporting period

*

from 1.2024 to 12.2024

1.2 Describe your business activities

*
STME has focused on product development, business growth and expansion of its operations. This has resulted in the release of a Veterinary product, which has shown strong growth potential in the UK and abroad. STME has continued the development of the SID dock for the human market after strong interest from the European market.

1.4 Number of employees in the reporting year

*
14

1.4.1 Full-time equivalent (FTE) or headcounts

*
Headcounts

1.5 Let us know if your company is a parent company or subsidiary

*
Not applicable

Commitment and Targets *

2.1 Net zero target year

*
2050

2.1.1 Base year

*
2023

2.2 Near-term target

*

25% of intensity scope 1+2 emission reduction from my base year by 2035

2.3 Provide any additional comments or context on your net zero and near term targets.

*
STME is a start-up company developing a circular economy to reuse volatile anaesthetic agents, which are potent greenhouse gases. We are looking to expand and invest in our processing operations over the next few years. When paired with a growing customer base, this will likely increase the company\'s carbon footprint in the near future. STME is in the process of submitting our Carbon Reduction Plan as part of the NHS Evergreen Sustainable Supplier Assessment. Due to limited resources, we plan to meet the criteria, which include Scope 1, 2, and a subset of Scope 3 emissions (see recorded categories in Value Chain Emissions).

Own Emissions *

3.1 To reduce emissions in line with my commitment, my company has a plan and is taking action

*
Yes

Energy consumption

3.2 Total energy consumption

*
17211 kwh

3.3 Renewable energy

*
17211 kwh

Scope 1 emissions

3.4 Scope 1 emissions

*
5.627 metric tons CO2e

Scope 2 emissions

3.5 Location based scope 2 emissions

*
0.894 metric tons CO2e

3.6 Market based scope 2 emissions

*
0 metric tons CO2e

3.7 Describe your plans and actions taken to reduce scope 1 & 2 emissions.

*
The STME building has solar panels provided by the landlord, and STME is requesting more be installed with electric charging points.

3.8 Describe the calculation methodology and comment on the data accuracy, including any tools/methods used to calculate.

*
The methodology used to generate the data in this report has relied mostly on spend-based calculations. This relied on reviewing purchase orders to generate the required information. Therefore, there has been a focus on using the available data consistently. The GHG Conversion factors 2024 spreadsheet was used to calculate CO2 equivalence: https://assets.publishing.service.gov.uk/media/6722567487df31a87d8c497e/ghg-conversion-factors-2024-full_set__for_advanced_users__v1_1.xlsx

Value Chain Emissions (optional) *

Scope 3 emissions

4.1 Have you measured any of your scope 3 emissions?

*
Yes

4.1.1 Total scope 3 emissions

*
23.5 metric tons CO2e

Supply chain related - upstream emissions

4.1.5 Transportation and distribution (upstream)

*
0.167 metric tons CO2e

4.1.6 Waste in operations

*
0.162 metric tons CO2e

4.1.7 Business travel

*
6.677 metric tons CO2e

4.1.8 Employee commuting

*
16.332 metric tons CO2e

Customer related - downstream emissions

4.1.10 Transportation and distribution (downstream)

*
0.159 metric tons CO2e

4.1.17 Do you have a plan and are taking action to reduce emissions from your value chain?

*

Yes

STME is applying for an Innovate UK grant to fund assessments and improvements in the company's product line and operations.

4.2 Have you asked any of your suppliers to set a net zero target (either voluntarily or as a requirement)?

*
No

4.3 Have you communicated your commitment and actions to any of your customers?

*
Yes

4.4 Describe the calculation methodology and comment on the data accuracy and any tools used to calculate your scope 3 emissions.

*
The methodology used to generate the data in this report relied mostly on spend-based calculations. This relied on reviewing purchase orders to generate the required information. Therefore, there has been a focus on using the available data consistently. The GHG Conversion Factors 2024 spreadsheet was used to calculate CO2 equivalence: https://assets.publishing.service.gov.uk/media/6722567487df31a87d8c497e/ghg-conversion-factors-2024-full_set__for_advanced_users__v1_1.xlsx

Climate Solutions (optional) *

5.1 Do you classify any of your existing goods and/or services as a climate solution?

*
Yes

5.2 What percentage of your total revenue comes from sales of climate solutions?

*
100 %

5.3 Provide descriptions/names of your climate solutions:

*
STME was established to prevent the release of volatile anaethetic drugs into the atmosphere. These drugs are potent greenhouse gases, which are minimally metabolised by the body (<5%). It is common practice to expel them into the atmosphere after an operation. STME dock solutions for human and veterinary markets capture the expelled drug. Ultimately, STME plans to reintroduce the recovered drug back to the market after reprocessing and purification. The company is in the process of scaling up this process for the market.

5.4 Methodology used to assess these as climate solutions, and third party which has validated the assessment, if any:

*
As of this report, STME has not had a third party validate the company\\\'s emissions.

Management, Strategy and Climate Risk (optional) *

6.1 What governance processes do you have in place for your climate strategy? Choose as many as are applicable.

*

No processes in place

6.2 Have you started to identify and assess your companies climate risks and opportunities?

*
No - we plan to in the next 1-5 years

6.4 Have you taken actions this year outside of your emissions to accelerate climate progress?

*

No

-

Results, Challenges and Outlook *

7.1 Provide any additional comments or context on your annual results and progress from previous years.

*
STME is a start-up company that is reliant on outside investment. This has limited are potential for growth. We do expect to grow and will ultimately increase are overall carbon footprint. However, we take advantage of economies of scale to bring down the carbon footprint of our products as our customer base increases.

7.2 Do you face any key challenges in reducing emissions?

*

Reducing scope 1 emissions,Reducing scope 2 emissions,Reducing scope 3 emissions,Balancing emission reductions with business growth,Complexities in managing supply chain emissions,Slow societal and economic progress on climate action,Insufficient policies or government incentives,Insufficient funding,Inaccurate or insufficient data,Low return on investment,Limited influence over suppliers

7.3 Has there been any third party validation of the data submitted in this report?

*

No

-

SageTech Medical's Climate Report

SageTech Medical's Climate Report - 2024

Introduction *

1.1 Reporting year

*

2024

1.1.1 Reporting period

*

from 1.2024 to 12.2024

1.2 Describe your business activities

*
STME has focused on product development, business growth and expansion of its operations. This has resulted in the release of a Veterinary product, which has shown strong growth potential in the UK and abroad. STME has continued the development of the SID dock for the human market after strong interest from the European market.

1.4 Number of employees in the reporting year

*
14

1.4.1 Full-time equivalent (FTE) or headcounts

*
Headcounts

1.5 Let us know if your company is a parent company or subsidiary

*
Not applicable

Commitment and Targets *

2.1 Net zero target year

*
2050

2.1.1 Base year

*
2023

2.2 Near-term target

*

25% of intensity scope 1+2 emission reduction from my base year by 2035

2.3 Provide any additional comments or context on your net zero and near term targets.

*
STME is a start-up company developing a circular economy to reuse volatile anaesthetic agents, which are potent greenhouse gases. We are looking to expand and invest in our processing operations over the next few years. When paired with a growing customer base, this will likely increase the company\'s carbon footprint in the near future. STME is in the process of submitting our Carbon Reduction Plan as part of the NHS Evergreen Sustainable Supplier Assessment. Due to limited resources, we plan to meet the criteria, which include Scope 1, 2, and a subset of Scope 3 emissions (see recorded categories in Value Chain Emissions).

Own Emissions *

3.1 To reduce emissions in line with my commitment, my company has a plan and is taking action

*
Yes

Energy consumption

3.2 Total energy consumption

*
17211 kwh

3.3 Renewable energy

*
17211 kwh

Scope 1 emissions

3.4 Scope 1 emissions

*
5.627 metric tons CO2e

Scope 2 emissions

3.5 Location based scope 2 emissions

*
0.894 metric tons CO2e

3.6 Market based scope 2 emissions

*
0 metric tons CO2e

3.7 Describe your plans and actions taken to reduce scope 1 & 2 emissions.

*
The STME building has solar panels provided by the landlord, and STME is requesting more be installed with electric charging points.

3.8 Describe the calculation methodology and comment on the data accuracy, including any tools/methods used to calculate.

*
The methodology used to generate the data in this report has relied mostly on spend-based calculations. This relied on reviewing purchase orders to generate the required information. Therefore, there has been a focus on using the available data consistently. The GHG Conversion factors 2024 spreadsheet was used to calculate CO2 equivalence: https://assets.publishing.service.gov.uk/media/6722567487df31a87d8c497e/ghg-conversion-factors-2024-full_set__for_advanced_users__v1_1.xlsx

Value Chain Emissions (optional) *

Scope 3 emissions

4.1 Have you measured any of your scope 3 emissions?

*
Yes

4.1.1 Total scope 3 emissions

*
23.5 metric tons CO2e

Supply chain related - upstream emissions

4.1.5 Transportation and distribution (upstream)

*
0.167 metric tons CO2e

4.1.6 Waste in operations

*
0.162 metric tons CO2e

4.1.7 Business travel

*
6.677 metric tons CO2e

4.1.8 Employee commuting

*
16.332 metric tons CO2e

Customer related - downstream emissions

4.1.10 Transportation and distribution (downstream)

*
0.159 metric tons CO2e

4.1.17 Do you have a plan and are taking action to reduce emissions from your value chain?

*

Yes

STME is applying for an Innovate UK grant to fund assessments and improvements in the company's product line and operations.

4.2 Have you asked any of your suppliers to set a net zero target (either voluntarily or as a requirement)?

*
No

4.3 Have you communicated your commitment and actions to any of your customers?

*
Yes

4.4 Describe the calculation methodology and comment on the data accuracy and any tools used to calculate your scope 3 emissions.

*
The methodology used to generate the data in this report relied mostly on spend-based calculations. This relied on reviewing purchase orders to generate the required information. Therefore, there has been a focus on using the available data consistently. The GHG Conversion Factors 2024 spreadsheet was used to calculate CO2 equivalence: https://assets.publishing.service.gov.uk/media/6722567487df31a87d8c497e/ghg-conversion-factors-2024-full_set__for_advanced_users__v1_1.xlsx

Climate Solutions (optional) *

5.1 Do you classify any of your existing goods and/or services as a climate solution?

*
Yes

5.2 What percentage of your total revenue comes from sales of climate solutions?

*
100 %

5.3 Provide descriptions/names of your climate solutions:

*
STME was established to prevent the release of volatile anaethetic drugs into the atmosphere. These drugs are potent greenhouse gases, which are minimally metabolised by the body (<5%). It is common practice to expel them into the atmosphere after an operation. STME dock solutions for human and veterinary markets capture the expelled drug. Ultimately, STME plans to reintroduce the recovered drug back to the market after reprocessing and purification. The company is in the process of scaling up this process for the market.

5.4 Methodology used to assess these as climate solutions, and third party which has validated the assessment, if any:

*
As of this report, STME has not had a third party validate the company\\\'s emissions.

Management, Strategy and Climate Risk (optional) *

6.1 What governance processes do you have in place for your climate strategy? Choose as many as are applicable.

*

No processes in place

6.2 Have you started to identify and assess your companies climate risks and opportunities?

*
No - we plan to in the next 1-5 years

6.4 Have you taken actions this year outside of your emissions to accelerate climate progress?

*

No

-

Results, Challenges and Outlook *

7.1 Provide any additional comments or context on your annual results and progress from previous years.

*
STME is a start-up company that is reliant on outside investment. This has limited are potential for growth. We do expect to grow and will ultimately increase are overall carbon footprint. However, we take advantage of economies of scale to bring down the carbon footprint of our products as our customer base increases.

7.2 Do you face any key challenges in reducing emissions?

*

Reducing scope 1 emissions,Reducing scope 2 emissions,Reducing scope 3 emissions,Balancing emission reductions with business growth,Complexities in managing supply chain emissions,Slow societal and economic progress on climate action,Insufficient policies or government incentives,Insufficient funding,Inaccurate or insufficient data,Low return on investment,Limited influence over suppliers

7.3 Has there been any third party validation of the data submitted in this report?

*

No

-
Generating a PDF file. Please wait....